Loading…
GT Biopharma, Inc. is projected to decline to $0.351 by 2027, a -11% move from its current price of $0.3953. GTBP is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.3691 | $0.3951 | $0.4229 | -0.05% |
| May 30 | $0.3587 | $0.3949 | $0.4347 | -0.10% |
| May 31 | $0.3509 | $0.3947 | $0.444 | -0.15% |
| Jun 1 | $0.3444 | $0.3945 | $0.4519 | -0.20% |
| Jun 2 | $0.3387 | $0.3943 | $0.459 | -0.25% |
| Jun 3 | $0.3337 | $0.3941 | $0.4655 | -0.30% |
| Jun 4 | $0.3291 | $0.3939 | $0.4715 | -0.35% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3291 | $0.3939 | $0.4715 | -0.35% |
| Week 2 | $0.3044 | $0.3925 | $0.5062 | -0.70% |
| Week 3 | $0.2865 | $0.3912 | $0.534 | -1.05% |
| Week 4 | $0.2721 | $0.3898 | $0.5584 | -1.40% |
| Week 5 | $0.2598 | $0.3884 | $0.5806 | -1.74% |
| Week 6 | $0.2492 | $0.3871 | $0.6012 | -2.09% |
| Week 7 | $0.2397 | $0.3857 | $0.6206 | -2.43% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company that engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.
The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
GT Biopharma, Inc. trades under symbol GTBP and is currently priced at $0.3953. The stock has a market capitalization of $14.26M and ranks 4993 by market cap.
A major floor 49.2% below — a decisive break under it would weaken the trend.
The nearest floor, 31.2% below — buyers have tended to step in here.
The nearest ceiling, 11.3% above — a clean break opens room to run.
A major ceiling 88.7% above — clearing it would confirm fresh momentum.
Key GTBP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GTBP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.4158 | Sell | $0.406 | Sell |
| MA 10 | $0.4019 | Sell | $0.40 | Sell |
| MA 20 | $0.3769 | Buy | $0.3888 | Buy |
| MA 50 | $0.391 | Buy | $0.4058 | Sell |
| MA 100 | $0.48 | Sell | $0.5014 | Sell |
| MA 200 | $0.6479 | Sell | $0.8358 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.07 | Neutral |
| Stoch RSI (14) | 56.98 | Neutral |
| CCI (20) | 32.12 | Neutral |
| Williams %R (14) | -35.43 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 5.33 | Buy |
| Bollinger %B (20,2) | 0.60 | Neutral |
| Stochastic %K (14) | 64.57 | Neutral |
| TRIX (15) | 0.12 | Buy |
| Awesome (5,34) | 0.05 | Buy |
| Ultimate (7,14,28) | 49.86 | Neutral |
| Momentum (10) | 0.07 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 0.42 | Sell |
| ADX (14) | 14.61 | Neutral |
| ATR (14) | 0.03 | Info |
The 30-day technical picture shows bullish sentiment with RSI14 at 50. The stock’s price is trading near the 50-day simple moving average of $0.391 and well below the 200-day simple moving average of $0.6479. The 30-day range spans $0.2526 to $0.6187, with a defined support at $0.272 and resistance at $0.44.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.272 | $0.3953 | $0.477 | 0% | Neutral | |
| $0.2526 | $0.351 | $0.5278 | -11% | Neutral | |
| $0.20 | $0.295 | $0.4715 | -25% | Bearish | |
| $0.2728 | $0.4234 | $0.7097 | +7% | Neutral | |
| $0.2977 | $0.4842 | $0.8442 | +23% | Bullish | |
| $0.2715 | $0.4614 | $0.8321 | +17% | Neutral | |
| $0.2688 | $0.4764 | $0.8856 | +21% | Bullish | |
| $0.2084 | $0.3847 | $0.7347 | -3% | Neutral | |
| $0.1928 | $0.3701 | $0.7245 | -6% | Neutral | |
| $0.2416 | $0.482 | $0.9653 | +22% | Bullish | |
| $0.2485 | $0.5522 | $1.21 | +40% | Bullish | |
| $0.5731 | $1.27 | $2.93 | +222% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.272 | $0.3953 | $0.4736 | +0.00% |
| June 2026 | $0.3386 | $0.406 | $0.5046 | +2.72% |
| July 2026 | $0.3096 | $0.3776 | $0.4813 | -7.00% |
| August 2026 | $0.2987 | $0.3692 | $0.4797 | -2.23% |
| September 2026 | $0.303 | $0.3786 | $0.4996 | +2.56% |
| October 2026 | $0.2836 | $0.3581 | $0.4792 | -5.42% |
| November 2026 | $0.2622 | $0.3341 | $0.4525 | -6.71% |
| December 2026 | $0.2709 | $0.3482 | $0.477 | +4.22% |
Click any year to see its month-by-month GTBP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The GTBP price prediction for 2026 points to an average of $0.3953 (low $0.272, high $0.477) — a potential gain of 0% on today's $0.3953. Price action looks broadly range-bound.
In 2027, GTBP is projected to trade between $0.2526 and $0.5278, averaging $0.351 — a potential decline of -11% from today's $0.3953. That is -11% versus the projected 2026 average. A consolidation phase looks the most probable path here.
GT Biopharma, Inc.'s 2028 outlook centres on $0.295, within a $0.20 to $0.4715 range. That is -16% versus the projected 2027 average. That marks a -25% change versus current levels. A cyclical pullback looks likely — prices rarely move in a straight line.
By 2029, GTBP could reach as high as $0.7097, with a base case around $0.4234 and support toward $0.2728 — roughly +7% from $0.3953. A consolidation phase looks the most probable path here.
Expect GTBP to range from $0.2977 to $0.8442 through 2030. The $0.4842 average target implies a +23% move from current prices. That is up +14% on the projected 2029 average. Momentum favours further upside here.
The GTBP price prediction for 2031 points to an average of $0.4614 (low $0.2715, high $0.8321) — a potential gain of +17% on today's $0.3953. A consolidation phase looks the most probable path here.
In 2032, GTBP is projected to trade between $0.2688 and $0.8856, averaging $0.4764 — a potential gain of +21% from today's $0.3953. That is up +3% on the projected 2031 average. Momentum favours further upside here.
GT Biopharma, Inc.'s 2033 outlook centres on $0.3847, within a $0.2084 to $0.7347 range. That is -19% versus the projected 2032 average. That marks a -3% change versus current levels. A consolidation phase looks the most probable path here.
By 2034, GTBP could reach as high as $0.7245, with a base case around $0.3701 and support toward $0.1928 — roughly -6% from $0.3953. Price action looks broadly range-bound.
Expect GTBP to range from $0.2416 to $0.9653 through 2035. The $0.482 average target implies a +22% move from current prices. That is up +30% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The GTBP price prediction for 2040 points to an average of $0.5522 (low $0.2485, high $1.21) — a potential gain of +40% on today's $0.3953. Momentum favours further upside here.
In 2050, GTBP is projected to trade between $0.5731 and $2.93, averaging $1.27 — a potential gain of +222% from today's $0.3953. That is up +131% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in GTBP today (≈ 2,529.72426 GTBP) could be worth
$3,221.76
+$2,221.76 (+222%) by 2050 · US Dollar
Based on the average projected GTBP price of $1.27 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GTBPwould be worth at today's price.
$1,000 invested in GTBP on May 27, 2025 (≈ 346.020749 GTBP) would be worth
$136.78
-$863.22 (-86.3%) today · 0.14× · US Dollar
Based on a GTBP entry price of $2.89 vs. today's $0.3953.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.419 | $943.44 | -5.7% |
| 1 month ago | $0.28 | $1,411.79 | +41.2% |
| 3 months ago | $0.469 | $842.86 | -15.7% |
| 6 months ago | $0.79 | $500.38 | -50.0% |
| 1 year ago | $2.89 | $136.78 | -86.3% |
| All time (5.0y) ago | $512.7 | $0.77 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GTBP forecast.
Our base-case forecast reaches $0.79 around 2050.
Implied market cap at $0.79: $28.49M
In the multi-year forecast, the 2030 average price is $0.4842 with a 22.5% ROI and bullish sentiment. The 2040 forecast shows an average of $0.5522 with a 39.7% ROI and bullish sentiment, while 2050 projects an average of $1.27 with a 222.2% ROI and bullish sentiment. The forecast also includes other years with varying results, such as 2028 (average $0.295, -25.4% ROI) and 2029 (average $0.4234, 7.1% ROI).
Overall, the outlook indicates meaningful upside in the long term but includes years of contraction as part of a fluctuating path, and annualized volatility is listed at 100%.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $0.4842 with a ROI of 22.5% and bullish sentiment.
The long-range forecast includes bullish years (2030, 2040, 2050) with notable upside (2050 avg $1.27, ROI 222.2%), but also bearish years (e.g., 2028, ROI -25.4%). These are estimates, not guarantees.
Yes. The max forecast for 2050 is $2.93 with a ROI of 222.2% and bullish sentiment.
The 30-day range is $0.2526 to $0.6187. RSI14 is 50, sentiment is BULLISH, with SMA50 at $0.391 and SMA200 at $0.6479; support is $0.272 and resistance is $0.44.
Current price is $0.3953, market cap is $14.26M, and it ranks 4993.
GT Biopharma, Inc. Community Discussion
0Share your GT Biopharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.